Thus, this study demonstrated that utilizing LAT1 to improve brain drug delivery of perforin inhibitors and subsequently to enhance cell survival as well as to decrease both oxidative stress and inflammation is a feasible method for further drug development of drugs to combat neurodegenerative diseases like AD. Here, SLC7A5 is linked to Alzheimer disease.